Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Draxis, Pfizer deal

DRAX amended the terms of its license to PFE for European rights to DRAX's Anipryl

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE